Patient Buddy App for the Prevention of Avoidable Readmission in Cirrhosis

Status Completed

Clinical Trial Summary

To use the PatientBuddy App to reduce 30-day avoidable readmissions in cirrhotic patients using a patient and caregiver perspective.

Clinical Trial Description

Specific aim 1: To perform a pilot and feasibility study of disseminating current knowledge of readmission prevention in cirrhosis by using the Patient Buddy App with patient and caregiver interfaces. Eighty subjects (40 cirrhotic inpatients and 40 caregivers) will be enrolled and trained on the Patient Buddy at discharge. The App focuses on daily communication between patient/caregivers and the study team based on previously identified risk factors associated with readmission. The study team will initiate measures to prevent readmission using these communications. A detailed analysis of 30-day readmissions and input of the patients,caregivers and nurse manager will be performed to improve the App. Avoidable readmissions will be defined by a committee of hepatologists who is not part of the study at VCU.

Specific aim 2: To incorporate the opinion of key stakeholders (patients, caregivers and case managers) towards improving the Patient Buddy App in the prevention of avoidable readmission in cirrhosis. The input of the key stakeholders and the analysis of readmissions prevented during the pilot study will be used to update the App for preventing avoidable readmissions in future studies ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02534805
Study type	Observational
Source	Virginia Commonwealth University
Contact
Status	Completed
Phase
Start date	August 2015
Completion date	January 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01884415` - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis	Phase 3
Recruiting	`NCT05014594` - Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT	Phase 2
Not yet recruiting	`NCT03631147` - The Effect of Rifaximin on Portal Vein Thrombosis	N/A
Completed	`NCT04939350` - Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021
Completed	`NCT02528760` - To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis	N/A
Recruiting	`NCT05484206` - Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434	Phase 1
Not yet recruiting	`NCT05538546` - Baveno VI Criteria in Dynamic Monitoring of High-risk Varices in Compensated Cirrhotic Patients
Not yet recruiting	`NCT04053231` - Hepatocarcinoma Recurrence on the Liver Study - Part2
Recruiting	`NCT02983968` - Use of the French Healthcare Insurance Database
Completed	`NCT02705534` - Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1	Phase 3
Completed	`NCT02596880` - Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics	Phase 3
Completed	`NCT02247414` - Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection	Phase 4
Withdrawn	`NCT01956864` - Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer	Phase 1
Completed	`NCT02016196` - Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS	Phase 3
Completed	`NCT01447537` - Mechanisms Involved in the Benefits of an Exercise Programme in Patients With Cirrhosis	N/A
Completed	`NCT02113631` - Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir	N/A
Completed	`NCT01362855` - Advance Care Planning Evaluation in Hospitalized Elderly Patients
Active, not recruiting	`NCT01205074` - ¹³C-Methacetin Breath Test (MBT) Methodology Study	Phase 2/Phase 3
Completed	`NCT01476995` - Prognostic Indicators as Provided by the EPIC ClearView	N/A
Completed	`NCT01231828` - Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.	N/A